Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.

Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis (New EPOC): long-term results of a multicentre, randomised, controlled, phase 3 trial

Open access

Abstract

Background The interim analysis of the multicentre New EPOC trial in patients with resectable colorectal liver metastasis showed a significant reduction in progression-free survival in patients allocated to cetuximab plus chemotherapy compared with those given chemotherapy alone. The focus of the present analysis was to assess the effect on overall survival. Methods New EPOC was a multicentre, open-label, randomised, controlled, phase 3 trial. Adult patients (aged ≥18 years) with KRAS wild-type (codons 12, 13, and 61) resectable or suboptimally resectable colorectal liver metastases and a WHO performance status of 0–2 were randomly assigned (1:1) to receive chemotherapy with or without cetuximab before and after liver resection. Randomisation was done centrally with minimisation factors of surgical centre, poor prognosis cancer, and previous adjuvant treatment with oxaliplatin. Chemotherapy consisted of oxaliplatin 85 mg/m 2 administered intravenously over 2 h, l -folinic acid (175 mg flat dose administered intravenously over 2 h) or d , l -folinic acid (350 mg flat dose administered intravenously over 2 h), and fluorouracil bolus 400 mg/m 2 administered intravenously over 5 min, followed by a 46 h infusion of fluorouracil 2400 mg/m 2 repeated every 2 weeks (regimen one), or oxaliplatin 130 mg/m 2 administered intravenously over 2 h and oral capecitabine 1000 mg/m 2 twice daily on days 1–14 repeated every 3 weeks (regimen two). Patients who had received adjuvant oxaliplatin could receive irinotecan 180 mg/m 2 intravenously over 30 min with fluorouracil instead of oxaliplatin (regimen three). Cetuximab was given intravenously, 500 mg/m 2 every 2 weeks with regimen one and three or a loading dose of 400 mg/m 2 followed by a weekly infusion of 250 mg/m 2 with regimen two. The primary endpoint of progression-free survival was published previously. Secondary endpoints were overall survival, preoperative response, pathological resection status, and safety. Trial recruitment was halted prematurely on the advice of the Trial Steering Committee on Nov 1, 2012. All analyses (except safety) were done on the intention-to-treat population. Safety analyses included all randomly assigned patients. This trial is registered with ISRCTN, number 22944367. Findings Between Feb 26, 2007, and Oct 12, 2012, 257 eligible patients were randomly assigned to chemotherapy with cetuximab (n=129) or without cetuximab (n=128). This analysis was carried out 5 years after the last patient was recruited, as defined in the protocol, at a median follow-up of 66·7 months (IQR 58·0–77·5). Median progression-free survival was 22·2 months (95% CI 18·3–26·8) in the chemotherapy alone group and 15·5 months (13·8–19·0) in the chemotherapy plus cetuximab group (hazard ratio [HR] 1·17, 95% CI 0·87–1·56; p=0·304). Median overall survival was 81·0 months (59·6 to not reached) in the chemotherapy alone group and 55·4 months (43·5–71·5) in the chemotherapy plus cetuximab group (HR 1·45, 1·02–2·05; p=0·036). There was no significant difference in the secondary outcomes of preoperative response or pathological resection status between groups. Five deaths might have been treatment-related (one in the chemotherapy alone group and four in the chemotherapy plus cetuximab group). The most common grade 3–4 adverse events reported were: neutrophil count decreased (26 [19%] of 134 in the chemotherapy alone group vs 21 [15%] of 137 in the chemotherapy plus cetuximab group), diarrhoea (13 [10%] vs 14 [10%]), skin rash (one [1%] vs 22 [16%]), thromboembolic events (ten [7%] vs 11 [8%]), lethargy (ten [7%] vs nine [7%]), oral mucositis (three [2%] vs 14 [10%]), vomiting (seven [5%] vs seven [5%]), peripheral neuropathy (eight [6%] vs five [4%]), and pain (six [4%] vs six [4%]). Interpretation Although the addition of cetuximab to chemotherapy improves the overall survival in some studies in patients with advanced, inoperable metastatic disease, its use in the perioperative setting in patients with operable disease confers a significant disadvantage in terms of overall survival. Cetuximab should not be used in this setting. Funding Cancer Research UK.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s1470-2045(19)30798-3

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Trial profile
Figure 1 Trial profileCC BY-NC-ND · PubMed Central
Figure 2 Progression-free survival (A) and overall survival (B) in the primary analysis population
Figure 2 Progression-free survival (A) and overall survival (B) in the primary analysis populationCC BY-NC-ND · PubMed Central
Figure 3 Forest plot for overall survival CAPOX=capecitabine and oxaliplatin. CEA=carcinoembryonic antigen. IrMdG=irinotecan, 5-fluorouracil, and folinic acid. OxMdG=oxaliplatin, 5-fluorouracil, and folinic acid. *Mutation identified in primary cancer in KRAS (codons 12/13/61/117,146), NRAS (codons 12/13/61/117,146), or BRAF (V600E). †No mutation identified in primary cancer in KRAS (codons 12/13/61/117,146), NRAS (codons 12/13/61/117,146), or BRAF (V600E). ‡No mutation identified in primary cancer in KRAS (codons 12/13/61); no testing for remaining mutations (ie, KRAS [codons 117,146], NRAS [codons 12/13/61/117,146], or BRAF [V600E]).
Figure 3 Forest plot for overall survival CAPOX=capecitabine and oxaliplatin. CEA=carcinoembryonic antigen. IrMdG=irinotecan, 5-fluorouracil, and folinic acid. OxMdG=oxaliplatin, 5-fluorouracil, and folinic acid. *Mutation identified in primary cancer in KRAS (codons 12/13/61/117,146), NRAS (codons 12/13/61/117,146), or BRAF (V600E). †No mutation identified in primary cancer in KRAS (codons 12/13/61/117,146), NRAS (codons 12/13/61/117,146), or BRAF (V600E). ‡No mutation identified in primary cancer in KRAS (codons 12/13/61); no testing for remaining mutations (ie, KRAS [codons 117,146], NRAS [codons 12/13/61/117,146], or BRAF [V600E]).CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 25 references

Cited by

See all 257

Metadata

Authors
Bridgewater, J. A., Pugh, S. A., Maishman, T., Eminton, Z., Mellor, J., Whitehead, A., Stanton, L., Radford, M., Corkhill, A., Griffiths, G. O., Falk, S., Valle, J. W., O'Reilly, D., Siriwardena, A. K., Hornbuckle, J., Rees, M., Iveson, T. J., Hickish, T., Garden, O. J., Cunningham, D., Maughan, T. S., Primrose, J. N., Shablack, A., O'Callaghan, A., Moody, (. A., Allen, A., Brewster, A., Brown, A., Mayer, A., Davidson, B., Ton, C., Wilson, C., Lowdell, C., Rees, C., Baughan, C., Barlow, C., Purcell, C., Smith, D., Tsang, D., Brown, E., Walker, G., Malik, H., Cameron, I., Nolan, L., Hall, M., Tomlinson, M., Hill, M., Peterson, M., Finch-Jones, M., Kumar, N., Karanjia, N., Ali, N., Heaton, N., Ton, N. C., Ross, P., Praseedom, R., Thomas, R., Clive, S., Slater, S., Smith, S., Mudan, S., Bhattacharya, S., Essapen, S., Raouf, S., Fenwick, S., Cleator, S., Diamond, T., & Potter, V.
Affiliations
  • University College London (GB)
  • University of Southampton (GB)
  • University of Manchester (GB)
  • Manchester Royal Infirmary (GB)
  • Sheffield Teaching Hospitals NHS Foundation Trust (GB)
  • Basingstoke and North Hampshire Hospital (GB)
  • University Hospital Southampton NHS Foundation Trust (GB)
  • Bournemouth University (GB)
  • University of Edinburgh (GB)
  • Royal Marsden Hospital (GB)
Corresponding author
Bridgewater, John A
Venue
The Lancet Oncology
Publisher
Elsevier BV
Published
2020-03
Volume
21
Issue
3
Pages
398-411
ISSN
1470-2045 (ISSN-L)
OpenAlex
W3003259023
Cited by
255
References
25
Citations by year
2026: 30 · 2025: 35 · 2024: 34 · 2023: 33 · 2022: 42 · 2021: 56 · 2020: 25
FWCI
14.09
Type
journal article
Language
en
Open access
Licence
Locations
  • The Lancet Oncology (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • Research Explorer (The University of Manchester) (publishedVersion, cc-by-nc-nd)
  • Bournemouth University Research Online (Bournemouth University) (acceptedVersion)
  • ePrints Soton (University of Southampton) (acceptedVersion)
  • UCL Discovery (University College London) (submittedVersion)
  • Edinburgh Research Explorer (University of Edinburgh) (submittedVersion, cc-by-nc-nd)
Funders
  • NIHR Maudsley Biomedical Research Centre
  • Merck KGaA
  • Cancer Research UK (C317/A7275)
  • Royal Marsden NHS Foundation Trust
  • Institute of Cancer Research
  • Manchester Biomedical Research Centre
Topics
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
  • Health Sciences › Medicine › Surgery › Intraperitoneal and Appendiceal Malignancies
Keywords
colorectal liver metastases, cetuximab, systemic chemotherapy, oxaliplatin, FOLFOX, capecitabine, irinotecan, KRAS wild-type, hepatectomy, adjuvant therapy, overall survival, progression-free survival, EGFR inhibition, prognostic factors, prognostic score
MeSH terms
Cetuximab, Capecitabine, Irinotecan, Oxaliplatin, Aged, Antineoplastic Combined Chemotherapy Protocols, Leucovorin, Female, Fluorouracil, Follow-Up Studies, Humans, Liver Neoplasms, Male, Middle Aged, Neoplasm Recurrence, Local, Prognosis, Colorectal Neoplasms, Survival Rate

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis (New EPOC): long-term results of a multicentre, randomised, controlled, phase 3 trial. https://app.cochat.ai/papers/10.1016/s1470-2045(19)30798-3
The paper
Bridgewater, J. A., Pugh, S. A., Maishman, T., Eminton, Z., Mellor, J., Whitehead, A., Stanton, L., Radford, M., Corkhill, A., Griffiths, G. O., Falk, S., Valle, J. W., O'Reilly, D., Siriwardena, A. K., Hornbuckle, J., Rees, M., Iveson, T. J., Hickish, T., Garden, O. J., . . . Potter, V. (2020). Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis (New EPOC): long-term results of a multicentre, randomised, controlled, phase 3 trial. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(19)30798-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.